Nicolas-Xavier Bonne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nicolas-Xavier Bonne has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
Christophe Vincent
Department of Otology and Neurotology, CHRU de Lille, 59037, Lille, France
8 shared publicationsJean-Paul Lejeune
Department of Neurosurgery, CHRU de Lille, 59037, Lille Cedex, France
7 shared publicationsMarc Baroncini
Department of Neurosurgery, CHRU de Lille, 59037, Lille Cedex, France
7 shared publicationsC. Vincent
Department of otology and neurotology, CHU de Lille, 59000 Lille, France; Inserm U1008 - controlled drug delivery systems and biomaterials, université de Lille 2, CHU de Lille, 59000 Lille, France
5 shared publications- Michaël Risoud
Department of Otology and Neurotology, CHU Lille, 59000 Lille, France
4 shared publications - Pierre Fayoux
Pediatric ENT Department, CHU University Hospital, Lille, France
4 shared publications
Latest Publications
- 11 September 2026
- Published by Wiley in Otolaryngology–Head and Neck Surgery
Comparison of Osseointegration Outcomes in Percutaneous Bone‐Anchored Hearing Implants: Linear Incision Versus Minimally Invasive Techniques
Objective: To compare osseointegration outcomes between minimally invasive (MI) techniques and the linear incision (LI) technique for bone‐anchored hearing implant placement. Study Design: We conducted a retrospective, multicentre cohort study. Settings: Eight tertiary referral centers. Methods: Patients undergoing bone‐anchored hearing implant placement with either MI or LI techniques were included. The primary endpoint was implant extrusion within 180 days post‐placement, excluding trauma‐related cases. Surgical technique was the main exposure variable. A Cox proportional hazards model was used to assess the risk of extrusion between techniques, adjusting for potential confounders. Results: Eighty‐eight patients were included in the LI group and 117 in the MI group. The 180‐day non‐traumatic extrusion rate was 16.24% (95% confidence interval [CI], 10‐24) for the MI group and 1.14% (95% CI, 0.06‐7.1) for the LI group. Multivariable analysis demonstrated a significantly higher extrusion risk with MI techniques (HR = 10.1; 95% CI, 1.34‐76.7; P = .025). Conclusion: Our findings indicate a significantly increased extrusion risk with MI techniques compared with LI. Until higher‐level evidence becomes available, LI should be preferred in patients at risk of compromised osseointegration.
- 11 September 2026
- Published by Wiley in Otolaryngology–Head and Neck Surgery
Comparison of Osseointegration Outcomes in Percutaneous Bone‐Anchored Hearing Implants: Linear Incision Versus Minimally Invasive Techniques
Objective: To compare osseointegration outcomes between minimally invasive (MI) techniques and the linear incision (LI) technique for bone‐anchored hearing implant placement. Study Design: We conducted a retrospective, multicentre cohort study. Settings: Eight tertiary referral centers. Methods: Patients undergoing bone‐anchored hearing implant placement with either MI or LI techniques were included. The primary endpoint was implant extrusion within 180 days post‐placement, excluding trauma‐related cases. Surgical technique was the main exposure variable. A Cox proportional hazards model was used to assess the risk of extrusion between techniques, adjusting for potential confounders. Results: Eighty‐eight patients were included in the LI group and 117 in the MI group. The 180‐day non‐traumatic extrusion rate was 16.24% (95% confidence interval [CI], 10‐24) for the MI group and 1.14% (95% CI, 0.06‐7.1) for the LI group. Multivariable analysis demonstrated a significantly higher extrusion risk with MI techniques (HR = 10.1; 95% CI, 1.34‐76.7; P = .025). Conclusion: Our findings indicate a significantly increased extrusion risk with MI techniques compared with LI. Until higher‐level evidence becomes available, LI should be preferred in patients at risk of compromised osseointegration.
- 3 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Modèles précliniques de schwannomes vestibulaires pour l'évaluation d’une stratégie de réduction de dose d’irradiation par combinaison avec des thérapies ciblées
Contexte : Le schwannome vestibulaire (SV) est une tumeur bénigne de la gaine du nerf vestibulaire. La plupart des SV présentent une inactivation somatique bi-allèlique du gène suppresseur de tumeur NF2. L’inactivation congénitale du gène NF2 est impliquée dans le développement de la Neurofibromatose de type 2, une maladie génétique autosomique dominante prédisposant au développement de tumeurs multiples du système nerveux central et en particulier de schwannomes vestibulaires bilatéraux. Le traitement des schwannomes vestibulaires repose sur la chirurgie ou la radiothérapie délivrée en conditions stéréotaxiques. La réduction de la dose d’irradiation des schwannomes vestibulaires a permis d’améliorer le pronostic fonctionnel auditif tout en garantissant un taux de réponse satisfaisant. Pourtant de nombreux patients présenteront une surdité neurosensorielle progressive. Afin de poursuivre cette réduction de dose d’irradiation, des modèles biologiques fidèles récapitulant le statut d’inactivation du gène NF2 et la surdité neurosensorielle sont nécessaires à l’élaboration d’une approche préclinique.Problématique : Nous avons proposé de développer des systèmes modèles in-vitro et in-vivo compatibles avec l’étude de la radiosensibilité des schwannomes vestibulaires en combinaison avec des thérapies ciblant les voies de signalisation spécifiquement activées par la perte de fonction NF2.Méthodes : Les lignées cellulaires humaines de schwannomes vestibulaires NF2 (HEI_193, HEI_182), et de cellules de Schwann vestibulaire contrôle (HEI_286) ont été cultivées en essai clonogénique afin de déterminer le nombre d’unité formatrices de colonies à doses croissantes d’inhibiteur mTOR (Rapamycine), PI3K (GDC_0941), mTOR et PI3K (BEZ_235) pour déterminer le 50% d’inhibition de croissance (GI50%) puis en combinaison à doses croissantes de radiation gamma (Co60). La lignée cellulaire murine inactivée pour nf2 (SC4#9) a été utilisée pour réaliser des greffes syngéniques orthotopiques. La croissance des tumeurs a été suivie par IRM et bioluminescence et l’audition déterminée par potentiels évoqués auditifs. L’analyse histologique des cochlées a été réalisée par coloration en hématoxyline et éosine puis par fluorescence après clarification cochléaire. Des volumes complets ont été obtenus par microscopie confocale à balayage laser.Résultats : Les essais clonogéniques réalisés en Agarose ont identifié une radiorésistance relative des lignées humaines de schwannomes mutées pour NF2 par comparaison au contrôle humain non muté. Cette résistance identifiée en réponse à l’exposition à une dose unique d’irradiation gamma peut être contournée par l’inhibition de la voie mTOR au moment de l’irradiation restituant une sensibilité comparable au contrôle humain non muté. Une tendance à un bénéfice de l’association d’une inhibition mTOR à un inhibiteur PI3 kinase a été retrouvée à une dose maximum d’irradiation. Un modèle murin de schwannome vestibulaire qui récapitule la croissance dans l’angle ponto-cérébelleux et la perte d’audition a été développé par injection stéréotaxique dans le paquet acoustico faciale. Le suivi de croissance de ce schwannome a été caractérisé par IRM et bio-luminescence in-vivo. Enfin un protocole de clarification cochléaire a été adapté aux mammifères murins pour permettre l’étude histologique de cochlées intactes compatible avec l’étude de l’otoxicité des schwannomes et/ou de leur traitement .Conclusion : Les modèles décrits dans cette thèse permettent l’évaluation pré-clinique de stratégies thérapeutiques combinant thérapie ciblée et irradiation gamma en dose unique. L’amélioration des connaissances des mécanismes participant à l’ototoxicité des schwannomes et de leur traitement permettra d’améliorer le ciblage moléculaire afin de réduire les effets auditifs secondaires de la radiochirurgie.
- 3 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Modèles précliniques de schwannomes vestibulaires pour l'évaluation d’une stratégie de réduction de dose d’irradiation par combinaison avec des thérapies ciblées
Contexte : Le schwannome vestibulaire (SV) est une tumeur bénigne de la gaine du nerf vestibulaire. La plupart des SV présentent une inactivation somatique bi-allèlique du gène suppresseur de tumeur NF2. L’inactivation congénitale du gène NF2 est impliquée dans le développement de la Neurofibromatose de type 2, une maladie génétique autosomique dominante prédisposant au développement de tumeurs multiples du système nerveux central et en particulier de schwannomes vestibulaires bilatéraux. Le traitement des schwannomes vestibulaires repose sur la chirurgie ou la radiothérapie délivrée en conditions stéréotaxiques. La réduction de la dose d’irradiation des schwannomes vestibulaires a permis d’améliorer le pronostic fonctionnel auditif tout en garantissant un taux de réponse satisfaisant. Pourtant de nombreux patients présenteront une surdité neurosensorielle progressive. Afin de poursuivre cette réduction de dose d’irradiation, des modèles biologiques fidèles récapitulant le statut d’inactivation du gène NF2 et la surdité neurosensorielle sont nécessaires à l’élaboration d’une approche préclinique.Problématique : Nous avons proposé de développer des systèmes modèles in-vitro et in-vivo compatibles avec l’étude de la radiosensibilité des schwannomes vestibulaires en combinaison avec des thérapies ciblant les voies de signalisation spécifiquement activées par la perte de fonction NF2.Méthodes : Les lignées cellulaires humaines de schwannomes vestibulaires NF2 (HEI_193, HEI_182), et de cellules de Schwann vestibulaire contrôle (HEI_286) ont été cultivées en essai clonogénique afin de déterminer le nombre d’unité formatrices de colonies à doses croissantes d’inhibiteur mTOR (Rapamycine), PI3K (GDC_0941), mTOR et PI3K (BEZ_235) pour déterminer le 50% d’inhibition de croissance (GI50%) puis en combinaison à doses croissantes de radiation gamma (Co60). La lignée cellulaire murine inactivée pour nf2 (SC4#9) a été utilisée pour réaliser des greffes syngéniques orthotopiques. La croissance des tumeurs a été suivie par IRM et bioluminescence et l’audition déterminée par potentiels évoqués auditifs. L’analyse histologique des cochlées a été réalisée par coloration en hématoxyline et éosine puis par fluorescence après clarification cochléaire. Des volumes complets ont été obtenus par microscopie confocale à balayage laser.Résultats : Les essais clonogéniques réalisés en Agarose ont identifié une radiorésistance relative des lignées humaines de schwannomes mutées pour NF2 par comparaison au contrôle humain non muté. Cette résistance identifiée en réponse à l’exposition à une dose unique d’irradiation gamma peut être contournée par l’inhibition de la voie mTOR au moment de l’irradiation restituant une sensibilité comparable au contrôle humain non muté. Une tendance à un bénéfice de l’association d’une inhibition mTOR à un inhibiteur PI3 kinase a été retrouvée à une dose maximum d’irradiation. Un modèle murin de schwannome vestibulaire qui récapitule la croissance dans l’angle ponto-cérébelleux et la perte d’audition a été développé par injection stéréotaxique dans le paquet acoustico faciale. Le suivi de croissance de ce schwannome a été caractérisé par IRM et bio-luminescence in-vivo. Enfin un protocole de clarification cochléaire a été adapté aux mammifères murins pour permettre l’étude histologique de cochlées intactes compatible avec l’étude de l’otoxicité des schwannomes et/ou de leur traitement .Conclusion : Les modèles décrits dans cette thèse permettent l’évaluation pré-clinique de stratégies thérapeutiques combinant thérapie ciblée et irradiation gamma en dose unique. L’amélioration des connaissances des mécanismes participant à l’ototoxicité des schwannomes et de leur traitement permettra d’améliorer le ciblage moléculaire afin de réduire les effets auditifs secondaires de la radiochirurgie.
- 1 August 2018
- Published by Elsevier in European Annals of Otorhinolaryngology, Head and Neck Diseases
- Vol. 135 (4) , 259-264
Sound source localization
- 1 August 2018
- Published by Elsevier in European Annals of Otorhinolaryngology, Head and Neck Diseases
- Vol. 135 (4) , 259-264
Sound source localization
- 1 May 2018
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 168, 77-82
Progression of vestibular schawnnoma after GammaKnife radiosurgery: A challenge for microsurgical resection
- 1 May 2018
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 168, 77-82
Progression of vestibular schawnnoma after GammaKnife radiosurgery: A challenge for microsurgical resection
- 1 September 2017
- Published by Elsevier in European Annals of Otorhinolaryngology, Head and Neck Diseases
- Vol. 134 (4) , 221-224
Imaging and cell count in cleared intact cochlea in the Mongolian gerbil using laser scanning confocal microscopy
- 1 September 2017
- Published by Elsevier in European Annals of Otorhinolaryngology, Head and Neck Diseases
- Vol. 134 (4) , 221-224
Imaging and cell count in cleared intact cochlea in the Mongolian gerbil using laser scanning confocal microscopy
- 22 July 2017
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 135 (1) , 47-56
The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannoma
Neurofibromatosis type 2 (NF2), a neurogenetic condition manifest by peripheral nerve sheath tumors (PNST) throughout the neuroaxis for which there are no approved therapies. In vitro and in vivo studies presented here examine agents targeting signaling pathways, angiogenesis, and DNA repair mechanisms. In vitro dose response assays demonstrated potent activity of lapatinib and nilotinib against the mouse schwannoma SC4 (Nf2 −/−) cell line. We then examined the efficacy of everolimus, nilotinib, lapatinib, bevacizumab and radiation (RT) as mono- and combination therapies in flank and sciatic nerve in vivo NF2-PNST models. Data were analyzed using generalized linear models, two sample T-tests and paired T-tests, and linear regression models. SC4(Nf2 −/−) cells implanted in the flank or sciatic nerve showed similar rates of growth (p = 0.9748). Lapatinib, nilotinib and RT significantly reduced tumor growth rate versus controls in the in vivo flank model (p = 0.0025, 0.0062, and 0.009, respectively) whereas bevacizumab and everolimus did not. The best performers were tested in the in vivo sciatic nerve model of NF2 associated PNST, where chemoradiation outperformed nilotinib or lapatinib as single agents (nilotinib vs. nilotinib + RT, p = 0.0001; lapatinib versus lapatinib + RT, p < 0.0001) with no observed toxicity. There was no re-growth of tumors even 14 days after treatment was stopped. The combination of either lapatinib or nilotinib with RT resulted in greater delays in tumor growth rate than any modality alone. This data suggest that concurrent low dose RT and targeted therapy may have a role in addressing progressive PNST in patients with NF2.
- 22 July 2017
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 135 (1) , 47-56
The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannoma
Neurofibromatosis type 2 (NF2), a neurogenetic condition manifest by peripheral nerve sheath tumors (PNST) throughout the neuroaxis for which there are no approved therapies. In vitro and in vivo studies presented here examine agents targeting signaling pathways, angiogenesis, and DNA repair mechanisms. In vitro dose response assays demonstrated potent activity of lapatinib and nilotinib against the mouse schwannoma SC4 (Nf2 −/−) cell line. We then examined the efficacy of everolimus, nilotinib, lapatinib, bevacizumab and radiation (RT) as mono- and combination therapies in flank and sciatic nerve in vivo NF2-PNST models. Data were analyzed using generalized linear models, two sample T-tests and paired T-tests, and linear regression models. SC4(Nf2 −/−) cells implanted in the flank or sciatic nerve showed similar rates of growth (p = 0.9748). Lapatinib, nilotinib and RT significantly reduced tumor growth rate versus controls in the in vivo flank model (p = 0.0025, 0.0062, and 0.009, respectively) whereas bevacizumab and everolimus did not. The best performers were tested in the in vivo sciatic nerve model of NF2 associated PNST, where chemoradiation outperformed nilotinib or lapatinib as single agents (nilotinib vs. nilotinib + RT, p = 0.0001; lapatinib versus lapatinib + RT, p < 0.0001) with no observed toxicity. There was no re-growth of tumors even 14 days after treatment was stopped. The combination of either lapatinib or nilotinib with RT resulted in greater delays in tumor growth rate than any modality alone. This data suggest that concurrent low dose RT and targeted therapy may have a role in addressing progressive PNST in patients with NF2.
- 1 April 2017
- Published by Elsevier in European Annals of Otorhinolaryngology, Head and Neck Diseases
- Vol. 134 (2) , 117-120
How to perform 3D reconstruction of skull base tumours
- 1 April 2017
- Published by Elsevier in European Annals of Otorhinolaryngology, Head and Neck Diseases
- Vol. 134 (2) , 117-120
How to perform 3D reconstruction of skull base tumours
- 4 October 2016
- Published by Springer Nature in Child's Nervous System
- Vol. 32 (12) , 2403-2413
Pediatric neurofibromatosis type 2: clinical and molecular presentation, management of vestibular schwannomas, and hearing rehabilitation
This study aims to describe the clinical and molecular presentation of pediatric neurofibromatosis type 2 (NF2) and the subsequent management of vestibular schwannomas (VS) and hearing rehabilitation. This is a single-center retrospective study of neurofibromatosis type 2 diagnosed before the age of 18 years old from 1997. Natural history of vestibular schwannomas and surgical outcomes were evaluated using volumetric MRI, hearing, and facial nerve assessment. Patients included in chemotherapy protocols were excluded. From a database of 80 patients followed up for NF2 on a regular basis, 25 patients were eligible (11 sporadic cases, 14 inherited in five families). The mean age at diagnosis was 11.6 years old. The average clinical follow-up was 6.5 years. NF2 mutation was identified in 81 % of the probands. The average growth rate based on the maximum linear diameter (DGR) was 1.68 mm/year (n = 33, average follow-up 4.22 years) and 545 mm3/year in volumetric assessment (VGR) for VS larger than 1 cm (n = 21, average follow-up 3.4 years). In unoperated ears, hearing was stable in about 50 % of ears. The mean change in dB HL was 9.5 dB/year for pure-tone average and 3.5 for speech-recognition threshold (n = 34, 5.5 years 1–12). Eight children required removal through a translabyrinthine approach (mean follow-up was 4.5 years), six patients were operated on for hearing preservation (mean postoperative follow-up 4.3 years). Six patients were eligible for hearing rehabilitation with cochlear implantation (I), and five received placement of an auditory brainstem implant. Early diagnosis and treatment of small growing VS should be carefully discussed considering familial history and possible rehabilitation with a CI.
- 4 October 2016
- Published by Springer Nature in Child's Nervous System
- Vol. 32 (12) , 2403-2413
Pediatric neurofibromatosis type 2: clinical and molecular presentation, management of vestibular schwannomas, and hearing rehabilitation
This study aims to describe the clinical and molecular presentation of pediatric neurofibromatosis type 2 (NF2) and the subsequent management of vestibular schwannomas (VS) and hearing rehabilitation. This is a single-center retrospective study of neurofibromatosis type 2 diagnosed before the age of 18 years old from 1997. Natural history of vestibular schwannomas and surgical outcomes were evaluated using volumetric MRI, hearing, and facial nerve assessment. Patients included in chemotherapy protocols were excluded. From a database of 80 patients followed up for NF2 on a regular basis, 25 patients were eligible (11 sporadic cases, 14 inherited in five families). The mean age at diagnosis was 11.6 years old. The average clinical follow-up was 6.5 years. NF2 mutation was identified in 81 % of the probands. The average growth rate based on the maximum linear diameter (DGR) was 1.68 mm/year (n = 33, average follow-up 4.22 years) and 545 mm3/year in volumetric assessment (VGR) for VS larger than 1 cm (n = 21, average follow-up 3.4 years). In unoperated ears, hearing was stable in about 50 % of ears. The mean change in dB HL was 9.5 dB/year for pure-tone average and 3.5 for speech-recognition threshold (n = 34, 5.5 years 1–12). Eight children required removal through a translabyrinthine approach (mean follow-up was 4.5 years), six patients were operated on for hearing preservation (mean postoperative follow-up 4.3 years). Six patients were eligible for hearing rehabilitation with cochlear implantation (I), and five received placement of an auditory brainstem implant. Early diagnosis and treatment of small growing VS should be carefully discussed considering familial history and possible rehabilitation with a CI.
- 1 July 2016
- Published by Elsevier in Hearing Research
- Vol. 337, 65-69
Technical note for post-auricular route surgery in Mongolian gerbil
- 1 July 2016
- Published by Elsevier in Hearing Research
- Vol. 337, 65-69
Technical note for post-auricular route surgery in Mongolian gerbil
- 13 May 2016
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 129 (1) , 47-56
An allograft mouse model for the study of hearing loss secondary to vestibular schwannoma growth
Vestibular schwannoma is a benign neoplasm arising from the Schwann cell sheath of the auditory-vestibular nerve. It most commonly affects both sides in the genetic condition Neurofibromatosis type 2, causing progressive high frequency sensorineural hearing loss. Here, we describe a microsurgical technique and stereotactic coordinates for schwannoma cell grafting in the vestibular nerve region that recapitulates local tumor growth in the cerebellopontine angle and inner auditory canal with resulting hearing loss. Tumor growth was monitored by bioluminescence and MRI in vivo imaging, and hearing assessed by auditory brainstem responses. These techniques, by potentially enabling orthotopic grafting of a variety of cell lines will allow studies on the pathogenesis of tumor-related hearing loss and preclinical drug evaluation, including hearing endpoints, for NF2-related and sporadic schwannomas.
- 13 May 2016
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 129 (1) , 47-56
An allograft mouse model for the study of hearing loss secondary to vestibular schwannoma growth
Vestibular schwannoma is a benign neoplasm arising from the Schwann cell sheath of the auditory-vestibular nerve. It most commonly affects both sides in the genetic condition Neurofibromatosis type 2, causing progressive high frequency sensorineural hearing loss. Here, we describe a microsurgical technique and stereotactic coordinates for schwannoma cell grafting in the vestibular nerve region that recapitulates local tumor growth in the cerebellopontine angle and inner auditory canal with resulting hearing loss. Tumor growth was monitored by bioluminescence and MRI in vivo imaging, and hearing assessed by auditory brainstem responses. These techniques, by potentially enabling orthotopic grafting of a variety of cell lines will allow studies on the pathogenesis of tumor-related hearing loss and preclinical drug evaluation, including hearing endpoints, for NF2-related and sporadic schwannomas.